Szolt Sebestyen

Associate Professor

Strategic program(s):

Biography

Biograpy: Obtained his PhD in Hungary at University of Debrecen, where he became fascinated by biophysical techniques that he learned to use to study molecular interactions in living cells. He was further trained in the Babraham Institute In Cambridge (UK) and later at the ErasmusMC in Rotterdam (NL) where he as postdoctoral fellow has studied the molecular needs of genetic engineering of T cells for the immunotherapy of cancer. He continued his career at the UMCU in Utrecht, where he was appointed in 2014 as staff member of Section Applied within the Laboratory of Translational Immunology. He is currently focusing on the developement of novel gamma delta T cell-based immunotherapies and the better understanding of innate T cell and tumour cell interactions. Reserach interest: Tumour recognition of innate immune cells, Immune receptors , Genetic engineering

Strategic program(s):

Contact

zsebesty@umcutrecht.nl

Pure profile

Research groups

Tumor Immunology

Research aim

Our research aims to revolutionise cancer treatment by advancing innovative immunotherapies, ensuring safer, more effective therapies, and improving patient outcomes, ultimately transforming lives through cutting-edge translational cancer research.

Go to group

Recent publications

All publications

Targeting pediatric cancers via T-cell recognition of the monomorphic MHC class I-related protein MR1 Annelisa M Cornel, Loutje van der Sman, Jip T van Dinter, Marta Arrabito, Ester Dunnebach, Marliek van Hoesel, Thomas A Kluiver, Ana P Lopes, Noël M M Dautzenberg, Linde Dekker, Jorik M van Rijn, Denise A M H van den Beemt, Juliane L Buhl, Aimee du Chatinier, Farnaz Barneh, Yuyan Lu, Luca Lo Nigro, Anja Krippner-Heidenreich, Zsolt Sebestyén, Jurgen Kuball, Esther Hulleman, Jarno Drost, Sebastiaan van Heesch, Olaf T Heidenreich, Weng Chuan Peng, Stefan Nierkens
Journal for ImmunoTherapy of Cancer, 2024, vol. 12

Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML Vania Lo Presti, Angelo Meringa, Ester Dunnebach, Alice van Velzen, Aida Valera Moreira, Ronald W Stam, Rishi S Kotecha, Anja Krippner-Heidenreich, Olaf T Heidenreich, Maud Plantinga, Annelisa Cornel, Zsolt Sebestyen, Jurgen Kuball, Niek P van Til, S Nierkens
Journal for ImmunoTherapy of Cancer, 2024, vol. 12

BEHAV3D Maria Alieva, Mario Barrera Román, Sam de Blank, Diana Petcu, Amber L. Zeeman, Noël M.M. Dautzenberg, Annelisa M. Cornel, Cesca van de Ven, Rob Pieters, Monique L. den Boer, Stefan Nierkens, Friso G.J. Calkoen, Hans Clevers, Jürgen Kuball, Zsolt Sebestyén, Ellen J. Wehrens, Johanna F. Dekkers, Anne C. Rios
Nature protocols, 2024, vol. 19, p.2052-2084

Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit I. Johanna, A. Daudeij, F. Devina, C. Nijenhuis, B. Nuijen, B. Romberg, C. de Haar, J. Haanen, H. Dolstra, E. Bremer, Z. Sebestyen, T. Straetemans, I. Jedema, J. Kuball
Immuno-Oncology and Technology, 2023, vol. 20

Serpin B9 controls tumor cell killing by CAR T cells Thomas Kimman, Anne Slomp, Anne Martens, Sarah Grabherr, Shuang Li, Eline van Diest, Jan Meeldijk, Jurgen Kuball, Monique C. Minnema, Eric Eldering, Niels Bovenschen, Zsolt Sebestyén, Victor Peperzak
Journal for ImmunoTherapy of Cancer, 2023, vol. 11

Strategies to improve γδTCRs engineered T-cell therapies for the treatment of solid malignancies A D Meringa, P Hernández-López, A Cleven, M de Witte, T Straetemans, J Kuball, D X Beringer, Z Sebestyen
Frontiers in Immunology, 2023, vol. 14, p.1-7

Fellowships & Awards

2020: KWF/Alpe d'HuZes Research Project grant: Optimized Killing (OK) technology to empower engineered T or NK cells in the treatment of cancer.

2018: Dutch Cancer Society/KWF Unique High Risk Project: Empowering the T cell killing machinery to eradicate cancer cells and prevent outgrowth.